• Genmab’s petosemtamab-pembrolizumab combination met both primary endpoints in Phase 3 LiGeR-HN1 at the first interim analysis.
• Death risk fell 50% versus pembrolizumab in first-line PD-L1-positive recurrent/metastatic head and neck squamous cell carcinoma, regardless of HPV status.
• Overall survival improved (HR 0.50; 95% CI 0.37–0.67); objective response improved (odds ratio 3.17; 95% CI 2.06–4.89), both p<0.0001.
• The combination was generally well tolerated, with no new safety signals.
• Genmab plans to engage global regulators and submit full results for presentation at a future medical meeting.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genmab A/S published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610280940PRIMZONEFULLFEED1001280400) on October 28, 2026, and is solely responsible for the information contained therein.